Daily CSR
Daily CSR

Daily CSR

Daily news about corporate social responsibility, ethics and sustainability
Tags (2) : Mabwell

Mabwell Denosumab Biosimilars Pass ANVISA GMP Inspection

Mabwell Denosumab Biosimilars Pass ANVISA GMP Inspection
08/17/2026 | Companies
Mabwell, an innovation-focused biopharmaceutical company with an integrated end-to-end pharmaceutical value chain, announced that its wholly owned subsidiary, T-mab, has successfully completed the Brazilian Health Regulatory Agency (ANVISA) GMP on-site inspection for its denosumab biosimilar...
9MW0311, 9MW0321, ANVISA, biopharmaceuticals, biosimilars, Brazil pharmaceutical market, BRICS, denosumab biosimilars, global market expansion, GMP certification, ICH, Latin America, Mabwell, marketing authorization, Pakistan, pharmaceutical manufacturing, pharmaceutical regulatory approval, PIC/S, Prolia biosimilar, quality management system, T-mab, WHO, Xgeva biosimilar

Mabwell Advances 6MW5311 Bispecific Antibody for AML and Blood Cancers

Mabwell Advances 6MW5311 Bispecific Antibody for AML and Blood Cancers
04/16/2026 | Companies
Mabwell (688062.SH), an innovation-focused biopharmaceutical company with an integrated value chain, has announced that the National Medical Products Administration (NMPA) has accepted the Investigational New Drug (IND) application for its novel LILRB4/CD3 T cell engager (TCE) bispecific antibody,...
6MW5311, acute myeloid leukemia, AML, biopharmaceuticals, biotechnology, bispecific antibody, cancer research, CD3, chronic myelomonocytic leukemia, clinical trials, CMML, cytotoxicity, drug development, FDA, hematologic malignancies, immune synapse, immunotherapy, IND application, LILRB4, Mabwell, MM, multiple myeloma, NMPA, oncology, preclinical studies, stem cell transplantation, steric hindrance, T cell engager, targeted therapy, TCE technology, tumor inhibition


Want to write a piece for Daily CSR? Please contact us by email at editor[@]dailycsr.com